Src Promotes Metastasis of Human Non-Small Cell Lung Cancer Cells through Fn14-Mediated NF-κB Signaling

Wei Wang* ABCDEF 1,2
Feiyu Liu* ABCEF 3
Chaoyang Wang BC 2
Chengde Wang CD 2
Yijun Tang D 2
Zhongmin Jiang AE 1

* Wei Wang and Feiyu Liu contributed equally to this study

Corresponding Author: Zhongmin Jiang, e-mail: qyjiangzhongmin@sina.com
Source of support: Departmental sources

Background: Src and Fn14 are implicated in the aggressiveness of non-small cell lung cancer (NSCLC) cells, yet the molecular mechanism is not fully understood.

Material/Methods: The proliferation, migration, and invasion of HCC827 cells with Src knockdown were examined in vitro. The expression of Fn14 and the activation of NF-κB signaling pathway in Src-silenced HCC827 cells were detected by western blot. The role of Fn14 in Src-regulated cell migration/invasion and activation of NF-κB signaling was investigated by overexpressing Fn14 in Src knockdown NSCLC cells. Furthermore, the pro-metastatic role of Src was validated in a NSCLC metastasis mouse model.

Results: Knockdown of Src inhibited the proliferation, migration, and invasion of HCC827 cells, which was associated with reduced levels of Fn14, p-ικBα, p-IKKβ, and nuclear NF-κB p65. Overexpression of Fn14 restored the potential of migration and invasion as well as the activation of NF-κB signaling in Src-silenced NSCLC cells. In addition, silencing of Src suppressed lung metastasis of HCC827 cells in mice, and inhibited the expression of Fn14 and nuclear translocation of NF-κB p65 in vivo.

Conclusions: The data demonstrated that the Src/Fn14/NF-κB axis plays a critical role in NSCLC metastasis.

MeSH Keywords: Carcinoma, Non-Small-Cell Lung • Receptor Activator of Nuclear Factor-kappa B • src-Family Kinases

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/906266
**Background**

Lung carcinoma is one of the leading malignancies worldwide. According to global cancer statistics in 2011, lung carcinoma ranked first among all cancer types in males, and it accounted for 17% of the total of new cancer cases and 23% of the total cancer-related deaths [1–3]. Moreover, the incidence of lung carcinoma in women continues to increase in recent years, and lung carcinoma has become the second most commonly recognized cancer type [1]. The oncogenesis of lung cancer can be triggered by indoor/outdoor air pollution and exposure to occupational or environmental carcinogens. According to histology and cancer genetics, lung carcinoma is normally classified into two major types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [4]. Of these two types, NSCLC is diagnosed in approximately 85% of all lung carcinoma cases, and it can be further classified as adenocarcinomas, squamous cell carcinomas, and large cell carcinomas [4]. Currently, chemotherapy remains the standard therapeutic modality for advanced or metastatic NSCLC. However, the response rate is lower than 35% as front-line treatment and is even lower as a second-line option [5–7]. Therefore, it is critical to identify novel biological targets that are associated with oncogenesis and metastasis of NSCLC for the development of effective therapeutic strategies, in order to improve outcomes and survival of NSCLC patients.

Src has been implicated in the progression of NSCLC and other cancers, and several Src inhibitors are at the pre-clinical stage or in clinical trials [8]. Src kinase is a member of the Src family of kinases that are involved in the modulation of diverse cellular signal transductions [9]. Src is a tyrosine kinase that plays critical roles in tumor growth, metastasis, and angiogenesis, and thus it is recognized as a promising therapeutic target for various solid tumors [10,11]. Regarding NSCLC, upregulation of Src kinase is frequently detected, especially in active smokers with squamous cell lung carcinoma [8,12]: elevated expression of Src is observed in 60–80% of adenocarcinomas and bronchioalveolar cancers and in 50% of squamous cell carcinomas. Cheng et al. found that the positive effect of Src on NSCLC cell invasion was mediated by Fn14, a member of the tumor necrosis factor superfamily of cell surface receptors [13]. Additionally, Src-regulated NF-κB signaling has been demonstrated in various cancers [14,15]. Given the fact that Fn14 regulates the growth of NSCLC and SCLC cells via NF-κB signaling [15,16], we speculated that Src may activate NF-κB signaling via Fn14 in NSCLC cells.

To verify our hypothesis, the regulatory role of Src in the expression Fn14 and the activation of NF-κB signaling in NSCLC cells were investigated by a series of *in vitro* and *in vivo* experiments. NSCLC cell line HCC827 with high expression levels of Src and Fn14 was selected as the *in vitro* cell model and for the *in vivo* metastasis assay. The effect of Src knockdown on the proliferation, migration, and invasion of HCC827 cells were assessed. Moreover, the expression of Fn14 and the activation of NF-κB signaling in Src-silenced cells were determined. The Src/Fn14/NF-κB axis was further confirmed by the rescue effect of Fn14 overexpression in Src-silenced HCC827 and A549 cells. In addition, the Src/Fn14/NF-κB axis in NSCLC cell metastasis was validated in a mouse metastasis model.

**Material and Methods**

**Antibodies and reagents**

Antibodies against Fn14 (D121267) and Src (D120536) were purchased from Sango Biotech (Shanghai, China). Antibodies against IκBα (bs-1287R), phosphorylated IκBα (p-IκBα) (bs-18129R), IKKβ (bs-4880R), p-IKKβ (bs-3233R), and Histone H3 (bs-17422R) were purchased from Bioss (Beijing, China). Antibody against nuclear NF-κB p65 (PB0073) was purchased from Boster (Wuhan, China). Antibody against NF-κB p65 (10745-1-AP) used for immunofluorescent staining was purchased from Proteintech (China). Secondary goat anti-rabbit IgG-HRP (A0208), goat anti-mouse IgG-HRP (A0216), and cy3-labeled goat anti-mouse IgG (A0521) antibodies were purchased from Beyotime (Shanghai, China). Antibody against β-actin (sc-47778) was purchased from Santa Cruz (CA, USA). RNA Purified Total RNA Extraction Kit (RP1201) and super M-MLV reverse transcriptase (RP6502) were purchased from BioTeke (Beijing, China). Total Protein Extraction Kit (P0027) was purchased from Beyotime (Shanghai, China). MTT (M-2128) was purchased from Sigma (USA).

**Cells and animals**

NSCLC cell lines HCC827 (7-1150) and A549 (7-1006) were obtained from Chi Scientific (MA, USA). Cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) in a 37°C, 5% CO₂ atmosphere. BALB/c mice were provided by Changsheng Biotechnology (Liaoning, China) and housed in cages at room temperature (20°C to 25°C) under a constant humidity (55±5%) with access to food and water *ad libitum*. All the procedures on the animals were performed following the Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Ethics Committee of Shandong University.

**Vector construction and cell transfection**

Specific shRNA oligonucleotides targeting Src mRNA (at 5'-GGCTCCAGATTGCAACAA-3') and non-targeting version of shRNA were inserted into pRNA-H1.1 to form the
pRNA-H1.1-shSrc vector and pRNA-h1.1-NC vector. The coding sequence for Fn14 was amplified by PCR and ligated to pcDNA3.1+ to construct the Fn14 overexpression vector (pcDNA3.1-Fn14). NSCLC cells were transfected with different vectors using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

**Establishment of stable Src knockdown cell line**

HCC827 cells were divided into three groups: a) parental group, parental HCC827 cells; b) NC group, HCC827 cells transfected with the pRNA-H1.1-NC vector; and c) shSrc group, HCC827 cells transfected with the pRNA-H1.1-shSrc vector. Each group was represented by at least five replicates. After transfection, cells with stable Src knockdown or NC vector transfection were selected with G418 (200 μg/mL). The expression of Src in the three groups of HCC827 cells were determined by reverse transcription and real-time PCR (RT²-PCR) and western blotting.

**Overexpression of Fn14 in Src knockdown cell lines**

HCC827 and A549 cells with stable Src knockdown were further transfected with the Fn14 overexpression vector or the control pcDNA3.1+ vector: a) NC group, HCC827/A549 cells stably transfected with the pRNA-H1.1 vector; b) shSrc group, HCC827/A549 cells stably transfected with pRNA-H1.1-shSrc; c) shSrc+Vector group, Src-silenced HCC827/A549 cells transfected with pcDNA3.1+; and d) shSrc+Fn14 group, Src-silenced HCC827/A549 cells transfected with pcDNA3.1-Fn14. Forty-eight hours after transfection, the expression levels of Fn14 in different groups of cells were detected by RT²-PCR.

**In vivo metastasis assay**

Eighteen BALB/c mice were randomly divided into three groups: a) control group, mice received an injection of 10⁷ HCC827 cells (in 0.2 mL volume) via the tail vein; b) NC group, mice received an injection of 10⁷ NC-transfected HCC827 cells via the tail vein; and c) shSrc group, mice received a tail vein injection of 10⁷ Src-silenced HCC827 cells. The mice were raised under the same housing conditions for four weeks. Thereafter, all mice were sacrificed using the air embolism method, and the lungs were evaluated for metastatic surface nodules by gross visualization. The tumor tissues were harvested and preserved at −80°C for subsequent assays.

**RT²-PCR**

The total RNA was extracted using an RNA Purified Total RNA Extraction Kit following the manufacturer’s instructions. The RNA was reversely transcribed to cDNA for PCR amplification using Super M-MLV reverse transcriptase. The final RT-PCR reaction mix in 20 μL volume contained 10 μL SYBR GREEN Master Mix, 0.5 μL of each primer [Src, forward: 5’-GGCTCAACTCTCGGACACCC-3’, reverse: 5’-AGGCCGTCCTGCTTTTCTG-3’; β-actin (internal reference gene), forward: 5’-CTTATGCGTGTACACCTTCTTGG-3’, reverse: 5’-CCTGACCTTCACCTGGTTTACGTTT-3’], 1 μL cDNA template, and 8 μL RNase-free H₂O. The reaction was performed on an Exicycler™ 96 analyzer (BIONEER, South Korea) using the following thermal cycling parameters: a denaturation step at 95°C for 10 minutes, followed by 40 cycles of amplification of 95°C for 10 seconds, 60°C for 20 seconds, and 72°C for 30 seconds. The reaction was stopped at 25°C for 5 minutes. The relative expression levels of Src were calculated based on the formula of 2⁻^ΔCt.

**Western blotting assay**

Total cellular protein was extracted using the Total Protein Extraction Kit according to the manufacturer’s instructions. β-actin (for cytoplasmic protein) and Histone H3 (for nuclear protein) were used as internal reference proteins. The concentrations of the protein samples were determined using the BCA method. Subsequently, 40 μg proteins from each sample was subjected to 10% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) at 80 V for 2.5 hours, and the proteins were then transferred onto polyvinylidene difluoride (PVDF) membranes. After being rinsed with TTBS, the membranes were blocked with skimmed milk solution for one hour. Thereafter, the membranes were incubated with the primary antibodies [Fn14 (1: 1000), p-IKK(a) (1: 400), p-IKK(b) (1: 500), p-IκB (1: 500), NF-κB p65 (1: 400), β-actin (1: 1000) or Histone H3 (1: 500)] at 4°C overnight. Following four washes with TTBS, the membranes were incubated with HRP-conjugated secondary antibodies (1: 5,000) for 45 minutes at 37°C. After another six washes with TTBS, the blots were developed using the Beyo ECL Plus reagent and the images were recorded in the Gel Imaging System. The relative levels of the proteins of interest were calculated by the Gel-Pro-Analyzer (Media Cybernetics, USA).

**Colony formation assay**

The anchorage-independent growth capability determines the tumorigenicity of cancer cells. Thus, NSCLC cells were subjected to colony formation assay for the assessment of anchorage-independent growth. The cells were suspended in the culture media containing 10% FBS and 0.35% agarose, and then inoculated onto 35 mm plates at a density of 200 cells per plate. After culture at 37°C for two weeks, the colonies on the plates were stained with Wright-Giemsa stain for five minutes, and the number of colonies on each plate was counted using a microscope. Colony formation rate = colony number/inoculated cell number per plate ×100%.
**MTT assay**

The viability of HCC827 cells were measured by MTT assay. Cells at the exponential growth phase were plated in 96-well plates at a density of $3 \times 10^4$/well, and cultured for 96 hours. Every 24 hours, 5 mg/mL MTT was added into the selected wells for four-hour incubation at 37°C. Thereafter, the supernatant was aspirated and 200 μL DMSO was added into each well. The cell viability was represented by the OD$_{490}$ value which was measured using a microplate reader (ELX-800, BIOTEK, USA).

**Scratch assay**

The mobility of NSCLC cells after Src knockdown was evaluated by the scratch assay. Cells were seeded in a 24-well plate at a density of $2 \times 10^4$ cells/well, and reference points were marked to guarantee the same area of image acquisition. The cells were allowed to grow into a confluent monolayer at 37°C for 24 hours. Then the layer was scratched to form a cell-free straight line, and the debris at the edges of the scratch was removed by rinsing with PBS. Cell migration towards the middle of the scratch was recorded in reference with the reference points. Three images were captured with a phase-contrast microscope and the gap distances were measured at 0 hour, 12 hours, and 24 hours after scratching. The migration rate was defined as the percentage of gap closure and the data were analyzed with the ImageJ software (US National Institutes of Health).

**Transwell assay**

Then 200 μL medium containing $2 \times 10^4$ cells were plated in the upper chamber of a Transwell system (BSA-coated porous polycarbonate membrane with a pore size of 8 μm, Corning star, Cambridge, MA, USA). Each polycarbonate membrane was pre-coated with 40 μL Matrigel (1.5 mg/mL; BD Biosciences, San Jose, CA, USA) and incubated at 37°C for two hours to form a reconstituted basement membrane. Cells were allowed to migrate through the Matrigel and the porous membrane for four hours at 37°C. After removing the cells on the upper surface of the membrane, the cells on the lower surfaces of the membrane were stained with 1% (w/v) crystal violet for 30 seconds and numbered with the Image-Pro Plus 6.0 software (Nikon).

**Immunofluorescent detection**

Nuclear translocation of NF-κB p65 was detected by immunofluorescent staining. Cells were seeded in 14-well chambers. After having grown into a monolayer, the cells were fixed for 4% paraformaldehyde for 15 minutes and permeabilized with 0.5% Triton X-100 for 30 minutes. Then the cells were blocked with 10% goat serum for 15 minutes, and incubated with a primary rabbit polyclonal antibody against NF-κB p65 (1: 200) overnight at 4°C. The Cy3-labeled secondary antibody (1: 100) was added onto the cells and incubated for one hour. After being washed with PBS, the cells were stained with 4,6-diamino-2-phenyl indole (DAPI) for five minutes at room temperature. Following another three cycles of five-minute washes with PBS, the cells were imaged with a fluorescent microscope at 400x magnification.

**Hematoxylin and eosin (H&E) staining**

The histological changes in the lungs from different groups of mice were examined by hematoxylin and eosin (H&E) staining. The tissues were fixed with 4% formaldehyde, dehydrated in ascending concentrations of alcohol and permeated with dimethylbenzene. Subsequently, the tissues were embedded in paraffin, sectioned and stained with H&E. The stained sections were observed under a microscope at 100x magnification. Following H&E staining, the nuclei were stained blue and the cytoplasm was stained red.

**Statistical analysis**

The data were expressed as mean ±SD, and each assay was performed with at least three replicates. Multiple comparisons were performed using ANOVA followed by post-hoc Duncan test in order to control the type I error. Significance was accepted when the two-tailed p value was smaller than 0.05. All the statistical analyses and graph plotting were conducted using GraphPad Prism version 6.01 for windows (GraphPad Software).

**Results**

**Knockdown of Src suppressed the viability and anchorage independent growth of HCC827 cells**

As shown in Figure 1A, 1B, the expression of Src was inhibited in HCC827 cells stably transfected with pRNA-H1.1-shSrc. The cell viability represented by OD$_{490}$ readings increased with time in all three groups of cells (Figure 1C). However, after 48 hours of the assay, the difference in the OD$_{490}$ value between the shSrc group and the control or the NC group were statistically significant ($p<0.05$). The results implied a key role of Src in the proliferation of NSCLC cells. Moreover, the anchorage independent growth ability of tumor cells was critical to the process of tumorigenesis. Here, knockdown of Src decreased the colony number in the shSrc group, and the differences between the shSrc group and the other two groups were statistically significant (Figure 1D). These results demonstrated that Src plays an important role in the tumorigenicity and growth of NSCLC cells.
Figure 1. Knockdown of Src decreased cell viability and colony formation in HCC827 cells. (A) RT2-PCR validation of Src expression in HCC827 cells with or without Src knockdown. (B) Representative images and quantitative analysis of western blotting validation of Src expression. (C) Quantitative analysis of the effect of Src knockdown on cell viability. Silencing of Src significantly decreased the OD490 value in the shSrc group after 48 hours of the assay. (D) Representative images and quantitative analysis of anchorage independent growth of HCC827 cells with or without Src knockdown. Silencing of Src decreased the colony number formed in the shSrc group. * p<0.05 versus parental group.
Knockdown of Src inhibited migration and invasion of HCC827 cells

The high rate of metastasis in NSCLC is a key contributor to the poor prognosis of NSCLC patients. Thus, the function of Src in the migration and invasion abilities of HCC827 cells was studied. As demonstrated by the scratch assay, knockdown of Src in HCC827 cells led to delayed gap closure compared with parental HCC827 cells (Figure 2A). In addition, knockdown of Src reduced the invasiveness of HCC827 cells, as indicated by a significantly lower proportion of cells penetrating the Matrigel-coated polycarbonate membrane after Src knockdown (Figure 2B). Taken together, Src not only contributed to proliferation, but also promoted metastasis of NSCLC cells.

Overexpression of Fn14 restored the metastatic potential and activation of NF-κB signaling in Src-silenced NSCLC cells

Previous evidence suggests a potential association between Src and Fn14-mediated NF-κB signaling [13,15,16]. To verify the hypothesis on the Src/Fn14/NF-κB axis in NSCLC, the activation of the signaling molecules involved in the NF-κB pathway was detected by western blotting and immunofluorescent staining. Knockdown of Src in HCC827 cells resulted in decreased levels of Fn14, p-IκBα, p-Iκκβ, and nuclear NF-κB p65 as well as an increased level of IκBα (Figure 3A), implying the blockade of Fn14-mediated NF-κB signaling. Moreover, inhibited nuclear translocation of NF-κB p65 in Src-silenced cells was further validated by immunofluorescent detection (Figure 3B). Generally, inhibition of NF-κB signaling would lead to reduced aggressiveness in NSCLC cells [15–17]. In line with the previous findings, suppression of Fn14-mediated NF-κB signaling

Figure 2. Knockdown of Src impaired the migration and invasion abilities in HCC827 cells. (A) Representative images and quantitative analysis of the effect of Src knockdown on the migration of HCC827 cells, as assessed by the scratch assay. For both recording time points, cells with Src knockdown showed a delayed closure rate when compared with cells in the parental group. (B) Representative images and quantitative analysis of the Transwell assay results for the assessment of the effect of Src knockdown on the invasion of HCC827 cells. Knockdown of Src resulted in a lower number of HCC827 cells penetrating the Matrigel-coated polycarbonate membrane. * p<0.05 versus parental group. Magnification, 400×.
Figure 3. Knockdown of Src downregulated the expression of Fn14 and reduced the activation of NF-κB signaling in HCC827 cells. (A) Representative images and quantitative analysis of the effect of Src knockdown on the levels of Fn14 and the signaling molecules in the NF-κB pathway. Knockdown of Src induced the expression of Fn14, and elevated the levels of p-IκBα, p-IKKβ, and nuclear NF-κB p65. (B) Representative images of immunofluorescent detection of the effect of Src knockdown on the nuclear translocation of NF-κB p65. Silencing of Src restricted the translocation of NF-κB p65 into cell nuclei. * p<0.05 versus parental group. Scale bar, 50 μm.
Src knockdown was synchronized with inhibited proliferation and metastasis of HCC827 cells (Figures 1, 2). Thus, the Src/Fn14/NF-κB axis may play an indispensable role in the cellular activities of NSCLC cells.

To confirm the aforementioned notion, Fn14 was overexpressed in Src-silenced HCC827 and A549 cells by using a specific expression vector. Overexpression of Fn14 promoted the migration and invasion of Src-silenced HCC827 and A549 cells (Figures 4, 5). It was also found that overexpression of Fn14 in Src-silenced HCC827 and A549 cells increased the levels of p-IκBα, p-IKKβ, and nuclear NF-κB p65, and decreased the levels of IκBα (Figures 6, 7). The results showed that overexpression of Fn14 counteracted the inhibitory effect of Src knockdown on the NF-κB pathway, representing the key role of Fn14 in mediating Src-activated NF-κB pathway.
**Knockdown of Src inhibited NSCLC metastasis and Fn14-mediated NF-κB signaling in mice**

Based on the *in vitro* data that Src was involved in the migration and invasion of NSCLC cells, a NSCLC metastasis mouse model was employed to evaluate the effect of Src knockdown on NSCLC metastasis *in vivo*. As shown in Figure 8A, the number of gross lung tumors in the control group and the NC group were almost two-fold of that in the shSrc group (*p*<0.05). Similar to the *in vitro* data, the levels of Fn14 and nuclear NF-κB p65 were downregulated in the metastatic tumors derived from Src knockdown cells (Figure 8B). Results of the *in vivo* assay support the conclusion that Src plays a central role in NSCLC metastasis via Fn14-mediated NF-κB signaling.
Figure 6. Overexpression of Fn14 restored the activation of NF-κB signaling in Src-silenced HCC827 cells. (A) Representative images and quantitative analysis of the effect of Fn14 overexpression on the expression of Fn14 and the activation of the NF-κB signaling molecules in Src-silenced HCC827 cells. Overexpression of Fn14 elevated the levels of p-IκBα, p-IKKβ and nuclear NF-κB p65, representing the activation of Fn14-mediated NF-κB pathway in Src knockdown HCC827 cells. (B) Representative images of immunofluorescent detection of the effect of Fn14 overexpression on the nuclear translocation of NF-κB p65. Overexpression of Fn14 stimulated nuclear translocation of NF-κB p65. * p<0.05 versus the shSrc group. Scale bar, 50 μm.
Figure 7. Overexpression of Fn14 restored the activation of NF-kB signaling in Src-silenced A549 cells. (A) Representative images and quantitative analysis of the effect of Fn14 overexpression on the expression of Fn14 and the activation of the NF-kB signaling molecules in Src-silenced A549 cells. Overexpression of Fn14 elevated the levels of p-IκBα, p-IKKβ, and nuclear NF-κB p65, representing the activation of Fn14-mediated NF-kB pathway in Src knockdown A549 cells. (B) Representative images of immunofluorescent detection of the effect of Fn14 overexpression on the nuclear translocation of NF-kB p65. Overexpression of Fn14 stimulated nuclear translocation of NF-kB p65. * p<0.05 versus the shSrc group. Scale bar, 50 μm.
**Discussion**

Src kinase is emerging as a potential therapeutic target for combating the progression of NSCLC [10,11]. Inhibition of Src was previously shown to be effective in controlling the growth of lung cancer cells *in vitro* [18]. Consistently, knockdown of Src in the current study resulted in decreased cell proliferation and reduced metastatic potential in NSCLC cells. Moreover, as a complement to the previous reports, our data also indicated that the function of Src in the progression of NSCLC depended on Fn14-mediated activation of the NF-κB signaling pathway.

Aberrantly activated Src is associated with the oncogenesis of diverse types of human cancers, including those of the lung, prostate, pancreas, breast, and colon [19]. In normal physiological conditions, the activity of Src is suppressed via phosphorylation of the amino acid near the C-terminus [20]. Once the amino acid is dephosphorylated, the conformation of Src is changed, which subsequently results in the full activation of the kinase. Upregulated activity of Src initiates the signal transduction cascades involved in the emergence and progression of cancers [10]. Regarding lung cancers, increased expression of Src has been recorded in 50% of squamous cell carcinomas isolated from NSCLC patients [21]. In addition, the expression level of Src in NSCLC has been reported to be associated with the size of the solid tumor, particularly in adenocarcinomas [21]. In the current study, human lung adenocarcinoma cell line HCC827 with high expression of Src was employed as the *in vitro* model for NSCLC. It was found that knockdown of Src impaired proliferation and metastasis of HCC827 cells. In addition, silencing of Src in HCC827 cells was associated with downregulation of Fn14 and deactivation of the NF-κB pathway. According to Cheng et al., Src is an important regulator of Fn14 expression in NSCLC [13]. Moreover, in a previous report by...
Src plays a key role in the oncogenesis and metastasis of NSCLC. Knockdown of Src inhibits proliferation, migration, and invasion of human NSCLC cells and tones down NF-κB signaling. Overexpression of Fn14 in Src-silenced NSCLC cells rescues the cell phenotype and resumes the activation of the NF-κB pathway. Our data demonstrated the critical role of the Src/Fn14/NF-κB axis in NSCLC growth and metastasis, and the potential therapeutic value of this axis is worth further evaluation in the future.

Conclusions

11. Sarries C, Haura EB, Roig B et al: Pharmacogenomic strategies for developing customised chemotherapy in non-small cell lung cancer. Pharmacogenomics, 2002; 3(6): 763–80

12. Masaki T, Igarashi K, Tokuda M et al: pp60 c-src activation in lung adenocarcinoma. Eur J Cancer, 2003; 39(10): 1447–55

13. Cheng E, Whitsett TG, Tran NL, Winkles JA: The TWEAK receptor Fn14 is an Src-inducible protein and a positive regulator of Src-driven cell invasion. Mol Cancer Res, 2014; 13(3): 575–83

14. Funakoshi-Tago M, Tago K, Andoh K et al: Functional role of c-Src in IL-1-induced NF-κB activation: c-Src is a component of the IKK complex. J Biochem, 2005; 137(2): 189–97

15. Li X, Zhu W, Chen Z et al: Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway. Anti-cancer Drug, 2014; 25(10): 1152–64

16. Whitsett TG, Mathews IT, Cardone MH et al: Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res, 2014; 12(4): 550–59

17. Li J, Lau GK, Chen L et al: Interleukin 17A promotes hepatocellular carcinoma metastasis via NFκB-induced matrix metalloproteinasises 2 and 9 expression. Plos One, 2011; 6(7): e21816

18. Ceppi P, Papotti M, Monica V et al: Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Res, 2009; 8(11): 3066–74

19. Summy JM, Gallick GE: Src family kinase inhibitors in tumor progression and metastasis. Cancer Metast Rev, 2003; 22(4): 337–58

20. Macauley A, Cooper JA: Structural differences between repressed and de-repressed forms of p60c-src. Mol Cell Biol, 1989; 9(6): 2648–56

21. Mazurenko NN, Kogan EA, Zborovskaya IB, Kiseleva LF: Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer, 1992; 28(2–3): 372–77

22. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev Drug Discov, 2008; 7(5): 411–25